| GlaxoSmithKline AG - Havrix 1440, Injektionssuspension | | 00558 | | 02 | | Havrix 1440 | | Injektionssuspension | | J07BC02 | | Hepatitis A, inaktiviert, ganzes Virus | | 03.09.1993 | | |
| | Composition | | Vaccinum adsorbatum: hepatitis-A-virus inactivatus (HM175) 1440 U. corresp. proteina max. 0.4 µg, aluminii hydroxidum hydricum ad adsorptionem corresp. aluminium 0.5 mg, aminoacida cum phenylalaninum 166 µg, dinatrii phosphas, kalii dihydrogenophosphas, natrii chloridum, kalii chloridum, polysorbatum 20, aqua ad iniectabile, ad suspensionem pro 1 ml corresp. natrium max. 3.6 mg et kalium max. 0.5 mg, residui: neomycini sulfas. | | Packungsbestandteile | | Suspension injectable | | | | | | | | Principe actif | Concentr. | informations additionels |
|---|
| Hepatitis-A-Virus Inactivatus (Hm175) | 1440 U/ml correspond Protéine 0.4 µg/ml | Vaccinum adsorbatum |
| | BAG: Principe actif | Concentr. |
|---|
| Vaccinum Hepatitidis a Inactivatum Adsorbatum | 1440 U |
| | | | Agents auxilliaires | Concentr. |
|---|
| Aluminii Hydroxidum Hydricum ad Adsorptionem | | | Aminoacida cum Phenylalaninum | 166 µg/ml | | Disodium Phosphate | | | Potassium Chlorure | | | Potassium Dihydrogenophosphate | | | Sodium Chlorure | | | Polysorbatum 20 | |
| |
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 002 | | 31.84 | 51.05 | B | LS | Non |
|
|
